| |
| Overview |
Sugen Life Sciences (SLS) research programs utilize molecular biology and modern drug discovery technology platforms to identify novel compounds. Our discovery strategies will examine how the promise of select technologies and resource initiatives could be applied to expediting the delivery of safe and effective drugs to the clinic. |
| |
| Current Focus |
| New Chemical Entities (NCE) developed by SLS are now at various phases of preclinical development. |
| |
| SLS core competencies are : |
 |
Collagen-Induced Arthritis |
|
High Fat Diet-induced Metabolic syndrome |
|
Non-Alcoholic Fatty Liver Disease |
|
| |
We have several in-house innovative R&D programs focusing on novel anticancer agents. When these projects reach certain preset milestones, SLS would be interested to collaborate with other parties to either co-develop or out license these promising projects. |
| |
| |
| |
